Paige Britt

Logic-gated CAR T A2B543 enters EVEREST-2 arm 2, adding membrane-tethered IL-12 to boost solid-tumor potency while limiting toxicity.

Clinical trial data show ovarian cancer survival gaps narrow with diverse enrollment, but disparities persist after progression, spotlighting access, toxicity, and care barriers.

Phase 2 data show elenagen plus gemcitabine extends survival in platinum-resistant ovarian cancer with high CA-125, without added toxicity.

RB-1355 reprograms autologous macrophages to heat up lymphoma tumors, avoid lymphodepletion, and deliver fast 1-week cellular therapy.

Electronic symptom reports plus pediatric palliative care improve physical quality of life in advanced childhood cancer when follow-up is consistent.

Screening rates fall as many women seek privacy and convenience; FDA‑cleared home HPV self-sampling may boost access and reduce disparities.

How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, surgery, and clinic efficiency.

New Uniphar deal widens European managed-access to Lymphir for relapsed CTCL, spotlighting targeted immunotherapy and manageable early-cycle risks.

FDA accepts tirabrutinib for accelerated review in relapsed/refractory CNS lymphoma, spotlighting strong phase 2 responses and a needed U.S. option.

Why most eligible lymphoma patients miss CAR T: experts urge stronger academic-community handoffs, clearer protocols, and smarter caregiver support.

How to manage Richter transformation: rapid biopsy, targeted combos, and early referral for CAR T or transplant, thus closing the access gap.

BTK inhibitors or time-limited venetoclax combos? Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life.

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials.

Phase 1 data show EB103 delivers 100% complete responses at high dose with manageable toxicity, offering a safer, durable option for high-risk B-cell NHL.

FDA lifts Yescarta limits for relapsed primary CNS lymphoma, expanding CAR T access with phase 1 safety data—what to know about neuro risks.

First-in-human DS3790 trial tests a CD37-targeted ADC for relapsed/refractory B-cell non-Hodgkin lymphoma, aiming to improve response durability and survival.

A recent study reveals significant racial disparities in ovarian cancer trial outcomes, highlighting the urgent need for improved diversity in clinical research.

FDA clears mRNA-based HPV test for primary screening, helping clinicians spot cancer-driving infections, cut overtreatment, and personalize care.

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Gemogenovatucel-T shows remarkable survival benefits in high-risk ovarian cancer patients, highlighting its potential as a new standard of care.

BioInvent's BI-1808 combined with pembrolizumab shows promising antitumor activity in recurrent ovarian cancer, offering hope for better treatment options.

The LARA trial reveals promising results for pembrolizumab and lenvatinib in treating recurrent clear cell gynecological cancer, showcasing effective antitumor activity.

A novel granule formulation of selumetinib shows promise for treating pediatric patients with inoperable neurofibromatosis type 1-related tumors, enhancing medication accessibility.

The COLIBRI study reveals that neoadjuvant dual immune checkpoint blockade enhances treatment outcomes for locally advanced cervical cancer, showing promising immune responses.

Nutritional status significantly impacts survival and treatment outcomes in cervical cancer patients, highlighting the need for routine nutritional screening.

A long-term study reveals that blinatumomab significantly enhances survival rates in infants with KMT2A-rearranged ALL, offering hope for improved treatment outcomes.

New findings reveal that tafasitamab significantly enhances progression-free survival in relapsed follicular lymphoma when combined with lenalidomide and rituximab.

Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

Researchers explore a promising nonchemotherapy treatment for low-grade serous ovarian cancer, combining ribociclib and letrozole to improve patient outcomes.